Introduction
============

Tobacco use is associated with substantial societal cost. Higher health care costs result from smoking-related medical conditions, including chronic obstructive lung disease, lung cancer, heart disease, impaired wound healing, and premature births, among others.[@b1-ppa-8-477] Tobacco use has also been associated with lost productivity, the cost of which is, within the United States, comparable in magnitude to the incremental cost increase associated with tobacco-related conditions.[@b1-ppa-8-477]

Yet not all of the health care costs associated with tobacco use appear to be a direct consequence of smoking-related illness. Evidence suggests that the health care utilization patterns of smokers may differ from those of nonsmokers and may contribute to greater medical costs as a result. Specifically, although some analysis has suggested that smokers may be less likely to have a primary care physician,[@b2-ppa-8-477] a recent study found no difference between smokers and nonsmokers in utilization of office visits.[@b3-ppa-8-477] A similar effort evidenced no significant difference in primary care utilization between smokers and nonsmokers, but did, however, find increased specialist visit rates among smokers.[@b4-ppa-8-477] Some of the observed findings may be due to differences in prevalence rates of medical conditions among smoking and nonsmoking subpopulations in these studies, some of which did not control for demographic and comorbid health concerns. Despite the heterogeneity of analytic methodologies, there appears to be a general consensus that smokers exhibit behavioral differences in their utilization of many types of health care services.

More specifically, these findings imply that smokers may be more reactive in their approach to care. Addressing this consideration, prior research has evaluated the impact of smoking status on use of preventive care and chronic condition management. Available data suggest that smokers are less compliant with recommended cancer screening[@b5-ppa-8-477] and immunizations[@b6-ppa-8-477] and have lower disease-specific medication adherence for chronic conditions.[@b7-ppa-8-477],[@b8-ppa-8-477] However, these earlier descriptive studies failed to incorporate depression as a potential confounder, which is particularly important given that depression is known to be more prevalent in smokers than in nonsmokers.[@b3-ppa-8-477],[@b9-ppa-8-477]

Depressive symptoms are associated with reduced compliance with recommended self-care[@b10-ppa-8-477],[@b11-ppa-8-477] and medication adherence,[@b10-ppa-8-477]--[@b12-ppa-8-477] along with increased health care costs.[@b10-ppa-8-477],[@b13-ppa-8-477] Little is known, however, about the confounding effect of depression on utilization of specific health care services among smokers.

For employers, the cost of workforce tobacco use is substantial. Employers may face incrementally higher expenditures associated with tobacco-related health conditions,[@b14-ppa-8-477],[@b15-ppa-8-477] as well as added costs associated with lost productivity,[@b3-ppa-8-477],[@b16-ppa-8-477] workers' compensation,[@b17-ppa-8-477] and disability.[@b3-ppa-8-477],[@b15-ppa-8-477] Additionally, employers may experience costs related to increased fire risk, maintenance of indoor air quality, and cleaning associated with smoke residue.[@b15-ppa-8-477]

In addition to a greater prevalence of tobacco-related illness and associated costs among smokers in commercially insured populations, prior studies indicate that health care utilization patterns may differ between smokers and nonsmokers. In cross-sectional studies, smokers have been shown to have higher hospitalization rates.[@b3-ppa-8-477],[@b4-ppa-8-477],[@b15-ppa-8-477] Emergency department use among smokers has been variable, with studies showing both greater emergency department utilization[@b3-ppa-8-477] and equal utilization[@b4-ppa-8-477] compared with nonsmokers. Comparisons of outpatient physician-visit utilization by smokers and nonsmokers have also yielded mixed results.[@b3-ppa-8-477],[@b4-ppa-8-477],[@b14-ppa-8-477]

Accordingly, this study was designed to evaluate the impact of smoking status on preventive care and disease-specific preventive care utilization, including medication adherence, in the adult health plan enrollees of a single employer. In order to more effectively characterize the independent impact of smoking on medical treatment compliance, depression was evaluated as a confounding variable.

Methods
=======

Study design
------------

This is a single-year, cross-sectional analysis using a medical and pharmacy claims database created for a single, large US employer with a national smoke-free workplace policy at the time the study data were collected. The database linked medical and pharmacy utilization and costs between 2008 and 2010, as well as health risk assessment data from 2009 and 2010. The analysis was limited to a comparison of current smokers and never-smokers. Because there was no available measure of the duration since smoking cessation in this population, it was not feasible to treat the former-smoker group as a homogenous population. As a result, former smokers were excluded from analysis.

Setting
-------

Subjects in this study were employees of a large, multinational company headquartered in the Midwestern United States. This employer has created a longitudinal, integrated database through Truven Health Analytics (Ann Arbor, MI, USA), which includes annual survey information about health and health risks (using the University of Michigan health assessment[@b18-ppa-8-477]) as well as medical, pharmacy, workers' compensation, absence, and presenteeism data. The health risk survey comprises a series of questions regarding individual lifestyle attributes, including smoking, physical activity, nutrition, stress, and other components, to which employees and spouses respond. Individuals submitting their completed assessment then receive an individualized report, describing opportunities for lifestyle improvement. Data for all survey takers is de-identified, and then aggregated and shared with the employer, who can then use the information to develop worksite or other lifestyle behavior-improvement programs to address the most prevalent concerns. This dataset has been described previously in a comparative analysis of health and productivity costs among smokers and nonsmokers.[@b3-ppa-8-477]

Data sources
------------

Benefit eligibility, medical and pharmaceutical claims, and survey data containing smoking status for the study population were extracted from the employer's database. The time period for all data was January 1, 2010 to December 31, 2010. The health risk survey (from University of Michigan),[@b18-ppa-8-477] administered to employees as a voluntary part of the benefits enrollment process during 2010, included a question about smoking status. These data were combined into a comprehensive analytic file.

Selection criteria
------------------

The study population consisted of employees and spouses/partners, aged 18 to 64 years, who were continuously enrolled in company medical coverage during 2010, and who had also completed the 2010 survey, providing a valid indication of smoking status. Employees were included in the analysis if they were actively working during the study period, were on a leave of absence, or had left employment and were directly paying for employer-provided health insurance during the study period.

Demographic variables
---------------------

Demographic descriptors were available from enrollment files, employment files, and survey responses. These included age and sex, ethnicity (classified as Caucasian or other), income, and educational achievement (college degree or not). Subsequent references to demographic variables include all the aforementioned, including income and education. Missing values for race, income, and education were replaced by the mean value in the sample of employees. Depending on the analysis, imputed data was required for 2.2% to 3.6% of individuals. Because of the low numbers, no sensitivity analysis was performed.

Definition of smoking status
----------------------------

Smoking status was determined based on self-reported smoking status from two sources: benefit enrollment information and the annual survey. As part of the benefit enrollment process, individuals were required to declare current smoking status in order to be eligible for a nonsmoking premium discount. The health assessments were utilized to identify prior smokers who responded affirmatively to the question: "How would you describe your cigarette smoking habits?" The response options were "still smoke", "used to smoke", and "never smoked". Nonsmokers were identified as those who responded negatively to both the survey question as well as the benefit enrollment smoking status question. Smokers were identified as those who responded affirmatively to either the benefit enrollment question or the health assessment question. There was a nearly 97% concordance among the individual responses recorded from the two data sources. The number of cigarettes smoked on a daily basis was not included as a variable in this analysis, as this information was not reliably available. Respondents who considered themselves prior smokers were excluded from further analysis.

Definition of chronic conditions
--------------------------------

Asthma, hypertension, diabetes, and coronary artery disease (CAD) were selected for inclusion in this study due to sufficient prevalence rates to permit statistical analysis. Individuals with these conditions were identified in accordance with proprietary Truven Health claims review algorithms, using medical and pharmacy services claims data (International Classification of Diseases, Ninth Revision \[ICD-9\] and Current Procedural Terminology codes, and National Drug Code codes, respectively). Other chronic conditions were excluded from analysis due to low prevalence rates.

Individuals with depression were identified as those who received facility or professional services provided under medical coverage that were reported on a claim with a principal diagnosis of depression (indicated as an ICD-9 code of 296.2X, 296.3X, or 311.XX).

Outcomes
--------

Health care compliance measures of cancer screening were assessed in comparison to the age and sex-specific recommendations from the US Preventive Service Task Force.[@b19-ppa-8-477] Prescription medication adherence for individuals with the identified chronic conditions was measured as the medication possession ratio (MPR), reported as the percentage of individuals with an MPR \>80% for the identified medication or medication class. The MPR is a commonly used method to estimate patient adherence with prescribed medications, and reflects the number of days of supplied medications divided by the total number of days during the study period.[@b20-ppa-8-477]

Chronic illness measures studied were extracted from the Healthcare Effectiveness Data and Information Set[@b21-ppa-8-477] and included: depression (acute and continuation treatment rates and medication adherence), hypertension (medication adherence), and asthma (medication adherence). Because of the low number of individuals with CAD, outcome measures included the presence of recommended prescriptions. In total, 14 outcomes (four screening measures and ten medication and adherence measures) were studied. The definitions for each of these measures, derived from the Healthcare Effectiveness Data and Information Set, and implemented by Truven, are shown in [Table 1](#t1-ppa-8-477){ref-type="table"}.

Analyses
--------

To estimate the independent effect of smoking status on compliance with recommended cancer screenings and MPR, several types of analyses were conducted. To adjust for population differences between smokers and nonsmokers, several covariates were included in analyses of those eligible for each compliance outcome measure. Demographic variables (shown in [Table 2](#t2-ppa-8-477){ref-type="table"}) included age, sex, geographic region of residence, education level (secondary school versus higher than secondary school), income (\< USD50,000/year versus ≥ USD50,000/year), union membership status, ethnicity (Caucasian versus non-Caucasian), and health plan type (preferred provider organization versus high-deductible health plan). Additionally, differences in relative prevalence and severity of comorbidities were controlled using the Charlson Comorbidity Index (CCI).[@b22-ppa-8-477] The CCI provides a statistically reliable method for quantifying the 10-year predicted mortality of 22 common chronic conditions and is used as a basis for comparison and controlling of populations with a range of chronic conditions in terms of prevalence and severity. Finally, depression was included as a covariate, in accordance with the above diagnostic approach.

All statistical analyses were performed using Stata software (StataCorp LP, Release 12.1; College Station, TX, USA). Basic differences between groups were compared using *t*-tests (means) and chi-square (percentages). Logistic regression models were estimated to derive the marginal impact of each variable on screening and MPR outcomes. Regression risk analysis or method of recycled predictions[@b23-ppa-8-477] was used to adjust the relative risks. Three sets of models were tested: one with only smoking as a predictor of outcomes; one with smoking along with demographic and CCI variables; and one with smoking, depression, and demographics along with CCI. A *P*-value of \<0.05 was considered significant.

The relative risk of screening and adherence rates by smokers compared to nonsmokers were calculated as the percent of smokers divided by the percent of nonsmokers exhibiting the behavior. Confidence intervals and *P*-values were estimated using bootstrapping with 5,000 repetitions. For measures with small patient numbers (especially beta blocker with myocardial infarction), some models failed to converge, resulting in a smaller number of actual repetitions. However, none of those relative risks was significant. Confidence intervals shown were based on the percentile method and bias-corrected using Stata 12.1 (bstat command).

Results
=======

After applying inclusion and exclusion criteria, 9,613 employees and spouses were eligible for the analyses. Of these, 2,394 were smokers (25%) and 7,219 (75%) were nonsmokers.

Population demographics of the two groups, smokers and nonsmokers, are shown in [Table 2](#t2-ppa-8-477){ref-type="table"}. While similar in sex distribution, benefit plan selection, and depression prevalence, smokers differed significantly from nonsmokers in other attributes. Smokers were older (45.0 years versus 43.4 years; *P*\<0.001), and a higher percentage of smokers than nonsmokers were Caucasian (90.5% versus 84.1%; *P*\<0.001). A lower percentage of smokers had attended college (42.4% versus 66.2%; *P*\<0.001) or earned over USD50,000 per year (39.7% versus 60.4%; *P*\<0.001).

Smokers had a higher prevalence of measured health conditions than nonsmokers. The CCI was significantly higher among smokers compared with nonsmokers (0.27 versus 0.22; *P*=0.001). Using eligibility for treatment or adherence metrics as indicators of prevalence ([Table 3](#t3-ppa-8-477){ref-type="table"}), smokers had significantly higher rates of treatment for depression (*P*\<0.05), CAD (*P*\<0.01), and previous myocardial infarction (*P*\<0.001). Smokers and nonsmokers were similar in their rates of use of hypertension and asthma medications. Nonsmokers had significantly higher rates of treatment for diabetes *(P*\<0.05). Due to their higher age, significantly more smokers were eligible for prostate, breast, and colorectal cancer screenings.

A small portion of the population was treated for depression (4.9%). Depression was not a significant predictor in any of the multivariate logit models predicting screening and adherence. Because depression did not contribute and results did not differ substantively from other models, only models without depression are reported.

Coefficients for logit models are shown in [Table 4](#t4-ppa-8-477){ref-type="table"}. Models for asthma and CAD had insufficient cases to run valid models. Controlling for demographics and CCI, smoking status (never-smokers versus current smokers) was a significant predictor of all cancer screening rates and hypertension adherence. Smoking was not a significant predictor of depression or diabetes medication adherence.

Of the covariates, age, region, salary, and plan type were significant factors in most models. Higher age groups were more likely to have recommended preventive screenings and higher medication adherence, except in the case of cervical cancer screening. Salary was positively associated with several outcomes. Living in the Midwestern US region was associated with higher rates of all outcomes, with the exception of a much lower likelihood of having prostate cancer screening. Union membership was the only demographic variable not significant in any models.

Adjusted relative risks for all outcomes are shown in [Table 5](#t5-ppa-8-477){ref-type="table"}. Smokers were less likely to receive recommended care and less likely to be adherent to medications in all instances. For all outcomes having 1,000 or more cases, smokers were significantly less likely to have recommended preventive care or an MPR \>80%. Of those taking depression medications, smokers had a relative risk of 0.79 of being compliant (*P*=0.10) compared to nonsmokers. The relative likelihood that smokers had recommended cancer screenings were consistently between 0.82 and 0.85 that of nonsmokers. Other relative risks ranged from 0.72 to 0.96.

Discussion
==========

In this study, current smokers were found to have significantly lower rates of compliance with recommended cancer screening as well as lower medication adherence for some of the identified chronic conditions. Importantly, the observed findings persisted despite adjustment for age, sex, ethnicity, income level, educational achievement, and comorbid conditions. Our results are consistent with prior studies[@b4-ppa-8-477],[@b6-ppa-8-477]--[@b8-ppa-8-477],[@b12-ppa-8-477],[@b24-ppa-8-477] showing lower compliance rates among smokers. Notably, although depression was more prevalent among smokers, it was not a significant factor in these results. Smokers were less compliant with all recommended screenings and medications, although results for conditions for which fewer than 500 patients were eligible for the metric were not significant. To our knowledge, this is the first study of treatment compliance among smokers that has incorporated this degree of statistical rigor.

Depression as a confounding factor
----------------------------------

In our analysis, depression had no significant independent impact on treatment adherence, despite its established association with smoking and its direct association with reduced treatment adherence, as described earlier in this paper. The lack of confounding impact may be explained in part by the use of medical and pharmacy claims data for depression diagnosis, which may underestimate the overall prevalence rate based on self-reported depression. Prior research suggests that the prevalence of self-reported depression may be significantly greater than that derived from claims data.[@b25-ppa-8-477] It is difficult to determine whether individuals with self-reported but untreated depression may have mild symptoms that are insufficient to cause them to access the health care system. Alternatively, it may be that, because smokers appear less likely to utilize the health care system, those with untreated depression may have more clinically significant symptoms.

Smoking status findings and potential explanations
--------------------------------------------------

While not specifically measured in this study, there are at least three possible explanations as to why smokers may have low compliance with recommended medical care. First, smokers may avoid regular contact with the health care system to minimize exposure to perceived pressure to stop smoking. However, in our prior analysis of this study population, no significant difference in ambulatory care clinician visit frequency was observed among smokers compared with nonsmokers, even following adjustment for demographic factors.[@b3-ppa-8-477] Second, smokers may not want to be reminded about the development of smoking-related health complications, and avoidance of regular medical contact minimizes this possibility. However, these two scenarios appear unlikely, since smokers might then be anticipated to have comparable medication adherence to nonsmokers -- a finding that was not observed in this study.

The third and perhaps most likely explanation is that, because smokers are already engaged in a known unhealthy lifestyle behavior, it may be easier for them to rationalize low compliance rates with recommended care on the basis of their at-risk lifestyle.[@b26-ppa-8-477] In essence, smoking may provide an excuse or justification for other unhealthy practices. In a prior analysis of the same population, we found that smokers had significantly fewer primary care visits and a higher use of emergency department services.[@b3-ppa-8-477] When considered in combination with the results from this study, the collective findings of lower rates of recommended cancer screening, lower medication adherence, and an apparently more reactive approach to health care utilization are consistent with this hypothesis.

Implication of results related to population health management
--------------------------------------------------------------

There are two important implications that can be inferred from our findings. First, these results suggest that the incremental increases in health care costs observed among smokers in some studies[@b4-ppa-8-477],[@b15-ppa-8-477] but not others[@b3-ppa-8-477],[@b27-ppa-8-477] may reflect two counteracting elements. First, tobacco-related illness may contribute to greater health care expenditure among smokers, along with a more symptom-driven approach to health care use. Offsetting these increased costs is the suboptimal compliance with recommended preventive care and medication use as observed in this study, the result of a more "reactive" use of health care services among smokers. While cross-sectional studies have not consistently demonstrated higher health care costs among smokers, it is possible that the observed suboptimal care compliance in this group may result in significantly greater associated health care costs if evaluated over time and in older populations. Accordingly, a compelling opportunity exists to better understand health care utilization and cost drivers among smokers, so as to more effectively target health management interventions to address the identified gaps in care.

Second, the health care implications resulting from poor adherence with recommended treatment are well established, and include suboptimal chronic condition management, increased hospitalization rates, and generally higher health care costs.[@b28-ppa-8-477]--[@b31-ppa-8-477] The finding of decreased treatment compliance among smokers with chronic conditions enhances the importance of directly assessing and managing this issue in this patient population.

Smoking cessation is already recognized as a high-value preventive care service[@b32-ppa-8-477] and, as such, is viewed as a priority in recent health care reform legislation. Health plan benefits for smoking cessation services are included among services requiring no out-of-pocket costs for non-grandfathered benefit plan enrollees, in accordance with the Patient Protection and Affordable Care Act.[@b33-ppa-8-477] In apparent recognition of this value, the recent final rules regarding benefit incentives for wellness programs provide plan sponsors the opportunity to incorporate an incentive of up to 50% of the total annual health care cost of a single employee as an inducement for smoking cessation.[@b34-ppa-8-477] The findings from this study provide additional support for the value of smoking cessation efforts.

Limitations
-----------

There are a number of limitations to this study. Our findings reflect the results of a single employer, and may not be generalizable to other business sectors. Importantly, this study includes only individuals (employees and their associated spouses) who were receiving commercial insurance benefits during the period of data collection and excluded individuals over the age of 65 years. It is unclear if the study findings can be generalized to other defined age, sex, and/or ethnicity subgroups.

As observed, the prevalence rates for the chronic conditions studied here are lower than might be anticipated in comparison to that seen among the general population. While these findings may be a result of a healthier workforce, it is also possible that the algorithms used to establish prevalence rates may have underestimated the total number of cases of each chronic condition.

While a conservative approach to measurement of condition prevalence rates adds credibility to the methodology, it may reduce the number of individuals identified with a condition (false negatives) or who are eligible for a specific metric. While the overall sample size was large, the small number of such individuals in specific subgroups may have limited the ability to reliably detect differences between smokers and nonsmokers.

Additionally, the identification of smoking status included in the study originated from self-reported data collected in the context of health assessment completion. Given the reduction in cost for nonsmokers, there may have been an incentive to falsely report smoking status. However, this may have been partially mitigated, since two different sources were being used to identify smokers. As such, while a majority of the workforce completed the health assessment, this population may not necessarily represent the findings from the broader employee population, thereby introducing a risk of self-selection bias into the study. Additionally, this study design does not account for elements of benefit design that may have impacted health care utilization. However, these were applied consistently across the entire workforce, and would not have been expected to selectively adversely impact either the smoker or nonsmoker population.

Further, use of MPR as a basis for establishing treatment adherence has inherent limitations. These include concerns related to changes in therapy, dose-splitting, medication sharing, and medication purchase outside the existing pharmacy benefit program, each of which may affect the measured MPR. Finally, an understanding of the primary and secondary preventive care utilization habits of former smokers would have provided additional insight into the interpretation of our findings. The inability to identify recent versus long-ago quitters made it impossible to gather reliable information about former smokers. Additional research is needed to better characterize both the nature and time course of treatment compliance changes that occur among individuals who are successful in their smoking cessation efforts.

Conclusion
==========

Analysis of cancer screening and compliance with recommended pharmacy care among health beneficiaries of a single large employer revealed significantly lower rates of recommended care among smokers relative to nonsmokers. In addition to smoking-related illness, health care costs associated with smokers may also arise from lower rates of compliance with recommended care. Employers and other stakeholders seeking to more effectively manage population health and health care cost drivers should incorporate consideration of these research findings into their strategic planning.
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###### 

Measure definitions for cancer screening and medication adherence

  Measure                                Numerator                                                                                                                                                                                                                                                                                          Denominator
  -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Breast cancer screening rate           Members eligible for measure who had a mammogram during the measurement year or in the prior year.                                                                                                                                                                                                 Women aged 42--69 years without a bilateral or two unilateral mastectomies during or prior to the measurement year.
  Colon cancer screening rate            Members eligible for measure who had colorectal cancer screening tests: a fecal occult blood test during the measurement year; a flexible sigmoidoscopy during the measurement year or within the previous 4 years; or a colonoscopy during the measurement year or within the previous 9 years.   Men and women aged 51--75 years, excluding people who had had a total colectomy or a diagnosis of colorectal cancer any time prior to or during the measurement period, based on claims included in the database.
  Cervical cancer screening rate         Women eligible for the measure who had facility or professional cervical cancer screening services provided under medical coverage.                                                                                                                                                                Women aged 21--64 years.
  PSA screen                             Men eligible for the measure who had facility or professional PSA screening services provided under medical coverage.                                                                                                                                                                              Men aged 50 years and older.
  Depression: acute treatment            Member eligible for measure who remained on the prescribed antidepressant medication during the first 84 days of treatment.                                                                                                                                                                        Men and women aged 18 years and older with a new diagnosis of depression and treated with an antidepressant during the measurement year.
  Depression: continuous treatment       Members eligible for measure who remained on that medication during the entire continuation phase (180 days beyond the initial prescription date).                                                                                                                                                 
  Depression: antidepressant adherence   Members eligible for measure with 300 or more days of depression medications on hand during the measurement year.                                                                                                                                                                                  Men and women aged 18 years and older with a primary or secondary depression diagnosis and a fill for an antidepressant during the measurement year.
  Diabetes: medication adherence         Members eligible for measure with 300 or more days of diabetes medications on hand during the measurement year.                                                                                                                                                                                    Men and women aged 18 years and older with a primary or secondary diabetes diagnosis and a fill for a diabetes medication during the measurement year.
  Hypertension: medication adherence     Members eligible for measure with 300 or more days of hypertension medications on hand during the measurement year.                                                                                                                                                                                Men and women aged 18 years and older with a primary or secondary hypertension diagnosis and a fill for a hypertension medication during the measurement year.
  Asthma: drug management                Members eligible for measure who were prescribed an inhaled corticosteroid or an acceptable alternative primary therapy asthma medication.                                                                                                                                                         Men and women aged 18--64 years with persistent asthma, excluding patients with a diagnosis of emphysema, chronic obstructive pulmonary disease, cystic fibrosis, or acute respiratory failure any time prior to or during the measurement period, based on claims included in the database.
  CAD lipid testing                      Members eligible for measure who had at least one lipid profile or all component tests during the measurement year.                                                                                                                                                                                Men and women aged 18 years and older with CAD.
  CAD: ACE inhibitor or ARB use          Members eligible for measure who were prescribed ACE inhibitor or ARB therapy.                                                                                                                                                                                                                     Men and women aged 18 years and older with CAD together with diabetes and/or left ventricular systolic dysfunction, excluding patients with ACE inhibitor contraindications such as angioedema, anuric renal failure, moderate or severe aortic stenosis, or pregnancy.
  CAD: antiplatelet treatment            Members eligible for measure who were prescribed antiplatelet therapy.                                                                                                                                                                                                                             Men and women aged 18 years and older with CAD, excluding patients with an allergy or intolerance to antiplatelet drugs, as well those with a documented reason (eg, medical, patient choice) for not having antiplatelet therapy prescribed.

**Abbreviations:** ACE, angiotensin-converting-enzyme; ARB, angiotensin receptor blocker; CAD, coronary artery disease; PSA, prostate-specific antigen.

###### 

Population demographics for smokers and nonsmokers in the study population

  Demographic attribute                                                  Nonsmokers (N=7,219)   Smokers (N=2,394)   *P*-value nonsmokers versus smokers
  ---------------------------------------------------------------------- ---------------------- ------------------- -------------------------------------
  Age (mean years)                                                       43.4                   45.0                \<0.001
  Sex (female)                                                           38.8%                  39.8%               0.388
  Preferred provider organization enrollee (others are CDHP enrollees)   79.6%                  80.0%               0.867
  Salaried worker (versus hourly)                                        47.8%                  17.3%               \<0.001
  Union membership (versus non-union)                                    6.1%                   10.8%               \<0.001
  Caucasian                                                              84.1%                  90.5%               \<0.001
  Midwestern US region                                                   77.1%                  77.5%               N/A
  Southern US region                                                     21.0%                  21.7%               N/A
  Western US region                                                      1.3%                   0.6%                N/A
  Northeastern US region                                                 0.6%                   0.2%                N/A
  Education beyond high school                                           66.2%                  42.4%               \<0.001
  Income ≥ USD50,000 per year                                            60.4%                  39.7%               \<0.001
  Depression diagnosis                                                   4.4%                   5.3%                0.083
  Charlson Comorbidity Index[@b22-ppa-8-477]                             0.22                   0.27                \<0.001

**Abbreviations:** CDHP, consumer-directed health plan; N/A, not available.

###### 

Percent of smokers and nonsmokers eligible for the chronic condition medication measures and cancer screening

  Quality of care parameter                 Nonsmokers (unadjusted)   Smokers (unadjusted)   *P*-value nonsmokers versus smokers
  ----------------------------------------- ------------------------- ---------------------- -------------------------------------
  Cervical cancer screening                 38.80%                    39.80%                 0.388
  Colon cancer screening                    30.80%                    34.30%                 0.002
  Breast cancer screening                   22.10%                    24.90%                 0.005
  Prostate cancer screening                 21.40%                    25.60%                 \<0.001
  Hypertension adherence to medications     14.90%                    15.30%                 0.591
  Diabetes adherence to medications         5.50%                     4.40%                  0.049
  Depression adherence to antidepressants   3.00%                     3.80%                  0.031
  Depression acute treatment rate           0.80%                     1.20%                  0.048
  Depression continuation treatment rate    0.80%                     1.20%                  0.048
  Asthma adherence to medications           0.70%                     0.50%                  0.296
  CAD antiplatelets fill                    0.50%                     1.10%                  0.001
  CAD dyslipidemia medication fill          0.50%                     1.10%                  0.001
  CAD any of the four medications           0.50%                     1.10%                  0.001
  CAD ACE inhibitor/ARB fill                0.30%                     0.70%                  0.027

**Abbreviations:** ACE, angiotensin-converting-enzyme; ARB, angiotensin receptor blocker; CAD, coronary artery disease.

###### 

Logistic regression model coefficients

  Demographic attributes                       Relationship between smoking status and compliance with recommended measures                                                                                                                                                                                                                             
  -------------------------------------------- ------------------------------------------------------------------------------ ----------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  N                                            1,441                                                                          500                                                   2,196                                                 3,755                                                  2,158                                                  3,044
  Smoking status odds ratios (95% CI)          0.745 (0.578, 0.961)                                                           0.877 (0.538, 1.429)                                  0.521 (0.418, 0.649)                                  0.717 (0.613, 0.839)                                   0.754 (0.606, 0.938)                                   0.747 (0.626, 0.891)
  Charlson comorbidity index[@b22-ppa-8-477]   1.101 (0.982, 1.235)                                                           0.998 (0.819, 1.215)                                  1.09 (0.948, 1.255)                                   0.966 (0.882, 1.057)                                   1.125 (1.022, 1.239)                                   1.099 (1.008, 1.198)
  Age categories                                                                                                                                                                                                                                                                                                                                        
   35--44 years                                                                                                               0.797                                                                                                       −0.265[\*\*](#tfn5-ppa-8-477){ref-type="table-fn"}                                                            
   45--54 years                                0.509[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}                            0.888[\*](#tfn4-ppa-8-477){ref-type="table-fn"}       0.178                                                 −0.499[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}                                                          
   55--64 years                                0.711[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}                            1.359[\*\*](#tfn5-ppa-8-477){ref-type="table-fn"}     0.310[\*](#tfn4-ppa-8-477){ref-type="table-fn"}       −0.618[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}   0.478[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}    −0.093
  Female                                       −0.263[\*](#tfn4-ppa-8-477){ref-type="table-fn"}                               −0.406                                                                                                                                                                                                                    0.089
  Plan type (PPO)                              0.157                                                                          0.243                                                 0.637[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}   0.357[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}    −0.168                                                 0.102
  Midwestern US region                         0.515[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}                            0.846[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}   0.362[\*\*](#tfn5-ppa-8-477){ref-type="table-fn"}     0.09                                                   −1.321[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}   0.067
  Salary                                       0.236                                                                          0.414                                                 0.566[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}   0.278[\*\*](#tfn5-ppa-8-477){ref-type="table-fn"}      0.13                                                   0.19
  Union                                        −0.189                                                                         −0.176                                                0.267                                                 --0.143                                                −0.204                                                 0.134
  Caucasian                                    −0.113                                                                         0.828[\*\*](#tfn5-ppa-8-477){ref-type="table-fn"}     −0.092                                                0.12                                                   0.441[\*](#tfn4-ppa-8-477){ref-type="table-fn"}        −0.077
  Income ≥ USD50,000 per year                  0.057                                                                          −0.223                                                0.075                                                 0.162[\*](#tfn4-ppa-8-477){ref-type="table-fn"}        0.121                                                  0.085
  Education beyond high school                 −0.144                                                                         −0.561[\*](#tfn4-ppa-8-477){ref-type="table-fn"}      0.142                                                 −0.101                                                 −0.038                                                 −0.085
  Constant                                     −0.129                                                                         −1.318[\*](#tfn4-ppa-8-477){ref-type="table-fn"}      0.182                                                 0.037                                                  −0.247                                                 −0.648[\*\*\*](#tfn6-ppa-8-477){ref-type="table-fn"}

**Notes:**

Statistically significant at 90% confidence level

statistically significant at 95% confidence level

statistically significant at 99% confidence level.

**Abbreviations:** CI, confidence interval; PPO, preferred provider organization.

###### 

Adjusted RRs for study outcomes of smokers and nonsmokers

  Quality of care parameter      N sample   \% compliant   Impact of smoking                           
  ------------------------------ ---------- -------------- ------------------- ------ ---------------- ---------
  Screening                                                                                            
  Breast cancer                  2,196      65.0           77.8                0.84   (0.78, 0.89)     \<0.001
  Cervical cancer                3,755      46.4           54.5                0.85   (0.79, 0.92)     \<0.001
  Colon cancer                   3,044      30.4           36.8                0.82   (0.73, 0.93)     0.001
  Prostate-specific antigen      2,158      30.5           36.1                0.84   (0.74, 0.97)     0.008
  Medications                                                                                          
  Hypertension                                                                                         
   Adherent                      1,441      59.7           66.3                0.90   (0.81, 0.99)     0.024
  Depression                                                                                           
   Acute treatment               85         69.0           75.6                0.91   (0.62, 1.35)     0.656
   Continuous treatment          85         37.9           47.6                0.80   (0.38, 1.52)     0.597
   Adherent                      305        37.0           46.9                0.79   (0.57, 1.07)     0.101
  Coronary artery disease                                                                              
   ACE inhibitor or ARB          40         81.3           96.8                0.84   (0.63, 2.05)     1.000
   Antiplatelets                 64         48.1           63.1                0.76   (0.45, 1.20)     0.225
   Lipid-lowering                64         92.6           95.4                0.97   (0.33, 1.10)     0.886
   Any of the four medications   64         92.6           97.3                0.95   (0.83, 1.01)     0.301
  Asthma                                                                                               
   Management rate               67         69.2           95.9                0.72   (0.51, \>10.0)   1.000
  Diabetes                                                                                             
   Adherent                      500        65.1           67.8                0.96   (0.81, 1.12)     0.610

**Abbreviations:** ACE, angiotensin-converting-enzyme; ARB, angiotensin receptor blocker; CI, confidence interval; RR, relative risk.
